Barclays lowered the firm’s price target on Sotera Health (SHC) to $17 from $18 and keeps an Overweight rating on the shares. Sentiment remains very bearish on the life science tools group from a focus on National Institutes of Health funding cuts impacting demand, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC: